Johnson & Johnson subsidiary Janssen Pharmaceutical Cos. reported a 14% reduction in the risk of major cardiovascular events for Invokana (canagliflozin) in the CANVAS outcomes trials, which was the same MACE reduction observed in the EMPA-REG trial for competing SGLT2 inhibitor Jardiance (empagliflozin), but it may be too early to declare the drugs' cardiovascular benefits – and Invokana's amputation risk – a class effect.
[Sidebar#SC098432]







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
